Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC).
Tsao CK, Galsky MD, Small AC, Yee T, Oh WK.
BJU Int · review; journal article · DOI 10.1111/j.1464-410x.2012.11445.x PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för enzalutamide. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
23 träffarNovel and bone-targeted agents for CRPC.
Fizazi K, Albiges L, Massard C, Escudier B, Loriot Y.
Ann Oncol · overall; conference proceedings · DOI 10.1093/annonc/mds353Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer.
Kohli M, Qin R, Jimenez R, Dehm SM.
Adv Urol · research-article; journal article · DOI 10.1155/2012/781459Increased survival with enzalutamide in prostate cancer after chemotherapy.
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS, AFFIRM Investigators.
N Engl J Med · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1056/nejmoa1207506Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born.
Schweizer MT, Antonarakis ES.
Ther Adv Urol · research-article; journal article · DOI 10.1177/1756287212452196[Therapy of castration-resistant prostate cancer].
Rauchenwald M, Bauernhofer T, De Santis M, Füreder T, Höltl W, Kramer G, Krause S, Loidl W, Oismüller R, Reissigl A, Schmeller N, Stackl W, Stoiber F, Krainer M.
Wien Klin Wochenschr · journal article; english abstract · DOI 10.1007/s00508-012-0206-1[Management of metastatic castration-resistant prostate cancer following docetaxel].
Beuzeboc P, Ropert S, Goldwasser F, Zerbib M.
Bull Cancer · review; journal article · DOI 10.1684/bdc.2012.1560Current and emerging treatments in the management of castration-resistant prostate cancer.
Shapiro D, Tareen B.
Expert Rev Anticancer Ther · review; journal article · DOI 10.1586/era.12.59Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, Edwards J, Isaacs WB, Nelson PS, Bluemn E, Plymate SR, Luo J.
Cancer Res · research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1158/0008-5472.can-11-3892Overcoming castration resistance in prostate cancer.
Tsao CK, Small AC, Galsky MD, Oh WK.
Curr Opin Urol · review; journal article · DOI 10.1097/mou.0b013e3283523b8b[Third generation anti-androgen therapy of advanced prostate cancer].
Ohlmann CH, Kamradt J, Stöckle M.
Urologe A · review; journal article; english abstract · DOI 10.1007/s00120-011-2760-yTherapeutic options for advanced prostate cancer: 2011 update.
Omlin A, de Bono JS.
Curr Urol Rep · comparative study; review; journal article · DOI 10.1007/s11934-012-0239-zOptimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.
Payne H, Bahl A, Mason M, Troup J, De Bono J.
BJU Int · research support, non-u.s. gov't; journal article · DOI 10.1111/j.1464-410x.2011.10886.xInteractions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.
Richards J, Lim AC, Hay CW, Taylor AE, Wingate A, Nowakowska K, Pezaro C, Carreira S, Goodall J, Arlt W, McEwan IJ, de Bono JS, Attard G.
Cancer Res · research support, non-u.s. gov't; research-article; journal article · DOI 10.1158/0008-5472.can-11-3980Methoxychalcone inhibitors of androgen receptor translocation and function.
Kim YS, Kumar V, Lee S, Iwai A, Neckers L, Malhotra SV, Trepel JB.
Bioorg Med Chem Lett · research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.bmcl.2011.12.141ARN-509: a novel antiandrogen for prostate cancer treatment.
Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L, Aparicio A, Dorow S, Arora V, Shao G, Qian J, Zhao H, Yang G, Cao C, Sensintaffar J, Wasielewska T, Herbert MR, Bonnefous C, Darimont B, Scher HI, Smith-Jones P, Klang M, Smith ND, De Stanchina E, Wu N, Ouerfelli O, Rix PJ, Heyman RA, Jung ME, Sawyers CL, Hager JH.
Cancer Res · research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1158/0008-5472.can-11-3948MDV3100 for the treatment of prostate cancer.
Mukherji D, Pezaro CJ, De-Bono JS.
Expert Opin Investig Drugs · review; journal article · DOI 10.1517/13543784.2012.651125[How should hormone therapy for castration-resistant prostate cancer be continued?].
Spahn M, Krebs M.
Urologe A · journal article; english abstract · DOI 10.1007/s00120-011-2738-9[Immunotherapy for metastatic prostate cancer: do we really need this?].
Heidenreich A.
Urologe A · journal article; english abstract · DOI 10.1007/s00120-011-2740-2Optimizing outcomes of advanced prostate cancer: drug sequencing and novel therapeutic approaches.
Crawford ED, Flaig TW.
Oncology (Williston Park) · review; journal articleAndrogen deprivation therapy as primary treatment for prostate cancer.
Cannata DH, Kirschenbaum A, Levine AC.
J Clin Endocrinol Metab · historical article; review; evaluation study; journal article; case reports · DOI 10.1210/jc.2011-2353Novel options for the treatment of castration-resistant prostate cancer.
Ohlmann CH, Merseburger AS, Suttmann H, Schilling D, Trojan L, Kempkensteffen C, Corvin S, Mathers MJ, Bastian PJ.
World J Urol · review; journal article · DOI 10.1007/s00345-011-0796-7Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer.
Eichholz A, Ferraldeschi R, Attard G, de Bono JS.
Mol Cell Endocrinol · review; journal article · DOI 10.1016/j.mce.2011.09.038